Company intelligence / Profile preview
Locate Bio
Nottingham, United Kingdomlocatebio.com ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Phase 1
01
Overview
Locate Bio’s lead product LDGraft™, a recombinant human BMP‑2 bone graft with advanced drug delivery/scaffold technology, is in clinical trials for lumbar interbody fusion and has received FDA Breakthrough Device designation. Other pipeline programs are at the preclinical stage or discontinued. No published pivotal clinical results yet.
- Therapeutic areas
- NeurologyInfectious DiseasesRheumatology
- Modalities
- Recombinant protein (rhBMP‑2)Synthetic biomaterial (calcium phosphate)Cell therapy (preclinical programs)Device (tissue scaffold/drug delivery)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Not specified in public sources.
Beyond the preview
Go deeper on Locate Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Locate Bio.